Table 1.
Transition probability matrix for ranolazine responders during the first cycle
| SAQAF EOT classification |
||||
|---|---|---|---|---|
| No | Monthly | Weekly | Daily | |
| SAQAF baseline classification | ||||
| No | – | – | – | – |
| Monthly | 2/2 (100%) 95% CI (34% to 100%) |
– | – | – |
| Weekly | 13/95 (13.7%) 95% CI (8% to 22%) |
82/95 (86.3%) 95% CI (78% to 92%) |
– | – |
| Daily | 2/47 (4.3%) 95% CI (1% to 14%) |
10/47 (21.3%) 95% CI (12% to 35%) |
35/47 (74.5%) 95% CI (60% to 85%) |
– |
The SAQAF Domain category ranolazine responders started in are depicted on the vertical axis (100=no, 61–99=monthly, 31–60=weekly and 0–30=daily symptoms) and the category they finished the double-blind trial period in is depicted on the horizontal axis. For example, 47 ranolazine responders began the study reporting ‘daily’ angina symptoms and 0 (0%), 35 (74.5%), 10 (21.3%) and 2 (4.3%) of these same patients reported having daily, weekly, monthly and no angina symptoms at the end of the trial.
EOT, end-of-treatment; SAQAF, Seattle Angina Questionnaire Angina Frequency.